Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07017699

A Study to Assess Deucravacitinib Safety in Pregnancy

The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy

Status
Recruiting
Phase
Study type
Observational
Enrollment
900 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Sex
Female
Age
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.

Conditions

Interventions

TypeNameDescription
DRUGDeucravacitinibAccording to product label
DRUGOther systemic treatments for PsOAccording to product label

Timeline

Start date
2025-03-21
Primary completion
2028-04-01
Completion
2029-02-28
First posted
2025-06-12
Last updated
2025-06-12

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07017699. Inclusion in this directory is not an endorsement.